Comparison 7. Factor Xa inhibitors versus VKA: concomitant antiplatelet use.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Stroke and other systemic embolic events	3	31774	Odds Ratio (M‐H, Fixed, 95% CI)	0.69 [0.61, 0.78]
1.1 Concomitant antiplatelet use	3	11279	Odds Ratio (M‐H, Fixed, 95% CI)	0.81 [0.66, 0.98]
1.2 No concomitant antiplatelet use	3	20495	Odds Ratio (M‐H, Fixed, 95% CI)	0.63 [0.54, 0.73]
2 Major bleedings	3	33654	Odds Ratio (M‐H, Fixed, 95% CI)	0.85 [0.77, 0.94]
2.1 Concomitant antiplatelet use	3	11267	Odds Ratio (M‐H, Fixed, 95% CI)	0.93 [0.80, 1.09]
2.2 No concomitant antiplatelet use	3	22387	Odds Ratio (M‐H, Fixed, 95% CI)	0.80 [0.70, 0.91]